Nippon Chemiphar Co., Ltd. (TYO:4539)
1,666.00
+19.00 (1.15%)
Jan 21, 2026, 3:24 PM JST
Nippon Chemiphar Revenue
Nippon Chemiphar had revenue of 7.68B JPY in the quarter ending September 30, 2025, with 0.71% growth. This brings the company's revenue in the last twelve months to 32.88B, up 4.25% year-over-year. In the fiscal year ending March 31, 2025, Nippon Chemiphar had annual revenue of 32.57B with 5.93% growth.
Revenue (ttm)
32.88B
Revenue Growth
+4.25%
P/S Ratio
0.18
Revenue / Employee
38.45M
Employees
855
Market Cap
6.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 32.57B | 1.82B | 5.93% |
| Mar 31, 2024 | 30.75B | -811.00M | -2.57% |
| Mar 31, 2023 | 31.56B | -947.00M | -2.91% |
| Mar 31, 2022 | 32.51B | 965.00M | 3.06% |
| Mar 31, 2021 | 31.54B | -215.00M | -0.68% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |